Navigation Links
Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/10/2010

BOSTON, Sept. 10 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, PTK 0796, a first-in-class aminomethylcycline, will be the subject of several poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  Dr. Stuart Levy, co-founder and Chief Scientific Officer of Paratek will also be delivering a talk at a symposium on antibiotic resistance at the conference.  ICAAC will be held in Boston, Massachusetts from September 12 - September 15, 2010.

More information on the poster sessions and symposium at ICAAC:Sunday, September 12, 11:30 a.m.– 1:30 p.m. EDTSession 002; Pharmacology of Oxazolidinones and Miscellaneous Antibacterial Agents

Location: Exhibit Hall B1

Poster:  A1-022, Board#19


  • Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic.

  • Sunday, September 12, 11:30 a.m.– 1:30 p.m. EDTSession 004; Antibiotic Therapy of Vascular Infections in Animal Models

    Location: Exhibit Hall B1

    Poster:  B-069, Board#70


  • Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model.

  • Sunday, September 12, 4:00 p.m.– 4:50 p.m. EDTSession 032; How 50 Years of Antibacterial Drug Development has Been Driven by Antibiotic Resistance

    Location: Room 052A

    Presentation:  456

    Presenter:  Stuart B. Levy, M.D.


  • A Tetracycline Renaissance.

  • Tuesday, September 14, 11:15 a.m.- 1:15 p.m. EDTSession 169; Antibiotic Resistance in Gram-Negative Bacteria Other than Enterobacteriacea

    Location: Exhibit Hall B1

    Poster:  C1-1413, Board#68


  • Studies on the Mechanism of Resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae.

  • Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDTSession 176; Anti-Staphylococcal Agents:  In Vitro/In Vivo Efficacy

    Location: Exhibit Hall B1

    Poster:  E-1569, Board#232


  • In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe.

  • Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDTSession 177; In Vitro Efficacy of Antimicrobials against Gram-Positive Bacteria

    Location: Exhibit Hall B1

    Poster:  E-1588, Board#254


  • Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009.

  • Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDTSession 191; Treatment Issues in Gram-Positive Infections

    Location: Exhibit Hall B1

    Poster:  L1-1760, Board#445


  • Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI):  Results of a PTK 0796 (PTK) Phase 2 Clinical Trial.
  • About Paratek PharmaceuticalsParatek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance.  Paratek is advancing novel compounds that can circumvent or block bacterial resistance.  Paratek's lead compound, PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae).  Oral and IV formulations of PTK 0796 were compared to Zyvox ® in a Phase 2 clinical study in complicated skin and skin structure infections (cSSSI).  In addition to PTK 0796, Paratek is also developing other tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.

    Based upon a growing body of clinical research and as part of its effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial tetracycline derivatives with improved activity in serious inflammatory and neurodegenerative diseases.  In addition, Paratek is encouraged by early evidence of the ability of tetracycline derivatives to affect mRNA splicing, as in spinal muscular atrophy (SMA).  Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

    Paratek has active collaborations with Novartis, Warner-Chilcott and FSMA to develop tetracycline-derived small molecule drugs for a range of uses, including bacterial infections, acne & rosacea and SMA.  Paratek is privately held and headquartered in Boston, Massachusetts, USA.  For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com.


    '/>"/>

    SOURCE Paratek Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
    2. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
    3. Martek to Present at Upcoming UBS Conference
    4. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
    5. Kendle to Present at Robert W. Baird & Co. 2010 Health Care Conference
    6. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
    7. Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference
    8. Lexicon to Present at Morgan Stanley Global Healthcare Conference
    9. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
    10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
    11. The Female Health Company to Present at Rodman & Renshaws Annual Global Investment Conference on Wednesday, September 15, 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
    (Date:2/16/2017)... , ... February 16, 2017 , ... ... case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on ... performed on a 55-year-old practicing female physician suffering from degenerative disc disease with ...
    (Date:2/16/2017)... and NEW YORK , ... the near completion of their $7M Series B financing, ... top of the $3.5M led by Mesa Verde Venture ... 2016.  These resources will be directed towards further accelerating ... PCDx, a comprehensive genomic profiling test and expanding the ...
    (Date:2/15/2017)... ... February 15, 2017 , ... Park Systems , a leader in ... operating software that drastically boosts productivity with single click reliable nanoscale images, is now ... of setting up and taking the image once done manually by the operator producing ...
    Breaking Biology Technology:
    (Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
    (Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
    (Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
    Breaking Biology News(10 mins):